Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171001 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2EPHX1FAAHSLC6A5ACE2 | |
| SCHEMBL171002 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2EPHX1FAAHSLC6A5ACE2 | |
| SCHEMBL8436544 | 0.98 | EPHX1 (0.48) | SMN1; SMN2EPHX1FAAHACE2FNTA | |
| SCHEMBL148701 | 0.98 | EPHX1 (0.48) | SMN1; SMN2EPHX1FAAHACE2FNTA | |
| SCHEMBL993588 | 0.98 | EPHX1 (0.48) | SMN1; SMN2EPHX1FAAHACE2FNTA | |
| SCHEMBL352163 | 0.98 | EPHX1 (0.48) | SMN1; SMN2EPHX1FAAHACE2FNTA | |
| SCHEMBL6758775 | 0.98 | EPHX1 (0.48) | SMN1; SMN2EPHX1FAAHACE2FNTA | |
| SCHEMBL10579468 | 0.98 | EPHX1 (0.48) | SMN1; SMN2EPHX1FAAHACE2FNTA | |
| SCHEMBL22325587 | 0.98 | EPHX1 (0.48) | SMN1; SMN2EPHX1FAAHACE2FNTA | |
| SCHEMBL9436902 | 0.98 | EPHX1 (0.48) | SMN1; SMN2EPHX1FAAHACE2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054892-A1 | THERAPEUTIC PEPTIDES | SHAPE THERAPEUTICS INC. (US) | 2024-03-14 | — | — | WO | claimed |
| WO-2024054892-A1 | THERAPEUTIC PEPTIDES | SHAPE THERAPEUTICS INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20120093746-A1 | AMINO ACID-MODIFIED ORGANOPOLYSILOXANE, MAKING METHOD, AND COSMETICS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
| EP-0805674-A1 | SKIN AND HAIR COSMETIC COMPOSITIONS | Kao Corporation (JP) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997014401-A1 | SKIN AND HAIR COSMETIC COMPOSITIONS | KAO CORPORATION (JP) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093746-A1 | AMINO ACID-MODIFIED ORGANOPOLYSILOXANE, MAKING METHOD, AND COSMETICS | DAO, AADAT, BCAT2 | SMN1; SMN2 724/4885EPHX1 2853/4885FAAH 2162/4885 |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | SMN1; SMN2 4444/4885EPHX1 4613/4885FAAH 3901/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | SMN1; SMN2 3894/4885EPHX1 4190/4885FAAH 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.